Literature DB >> 24189414

Metabolomic profiling for identification of potential biomarkers in the protective effects of modified Sinisan against liver injury in dimethylnitrosamine treated rats.

Cheng-Gang Liu1, Xiao-Li Wang, Xiao-Wei Du, De-You Jiang, Nai-Zhi Geng, Shuo-Xin Zhang, Yuan-Yuan Zhou, Hai-Xue Kuang.   

Abstract

Metabolomics is a new platform based on the comprehensive analysis of low molecular weight metabolites and provides a powerful approach to discover biomarkers in biological systems. Modified Sinisan (MSNS), a traditional Chinese medicine formula, displayed bright prospects in the prevention and therapy of liver injury. However, its molecular mechanism of hepatoprotective effects remains unclear. This paper was designed to explore the effects and potential mechanisms of MSNS against dimethylnitrosamine-induced liver injury. Global metabolic profiling was performed by ultra-performance liquid chromatography/electrospray ionization quadrupole time-of-flight mass spectrometry (UPLC/ESI-Q-TOF-MS) in conjunction with multivariate data analysis and pathway analysis. Eleven serum biomarkers were identified and pathway analysis results showed that phenylalanine, tyrosine and tryptophan biosynthesis, phenylalanine metabolism, tryptophan metabolism, retinol metabolism, tyrosine metabolism were perturbed by liver injury. More importantly, MSNS has showed satisfactory pharmacological effect on liver injury through partially regulating the perturbed pathways, correlates well to the biochemical and histopathological detection results. The present study proved that the robust metabolomics approach is promising for unraveling hepatoprotective effects of MSNS and these findings provide new insights into mechanisms of the liver injury, and its pathophysiologic processes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24189414     DOI: 10.1248/bpb.b13-00127

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways.

Authors:  Moonju Hong; Jeeyoun Jung; Hee-Sook Park; So Min Lee; Nam-Joo Jeong; Soon-Hee Kim; Kyoung-Won Lee; Ju-A Lee; Myung-Sunny Kim
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

2.  Effect of traditional Chinese medicine formula Sinisan on chronic restraint stress-induced nonalcoholic fatty liver disease: a rat study.

Authors:  Fafeng Cheng; Chongyang Ma; Xueqian Wang; Changming Zhai; Guoli Wang; Xiaolin Xu; Jie Mu; Changxiang Li; Zisong Wang; Xiaoyu Zhang; Wenchao Yue; Xin Du; Yajun Lian; Wenxiang Zhu; Xiangjun Yin; Zhen Wei; Wenjie Song; Qingguo Wang
Journal:  BMC Complement Altern Med       Date:  2017-04-07       Impact factor: 3.659

3.  Changes in hepatic metabolic profile during the evolution of STZ-induced diabetic rats via an 1H NMR-based metabonomic investigation.

Authors:  Minjiang Chen; Hong Zheng; Min Xu; Liangcai Zhao; Qianqian Zhang; Jingjing Song; Zhongwei Zhao; Siming Lu; Qiaoyou Weng; Xulu Wu; Weibin Yang; Xiaoxi Fan; Hongchang Gao; Jiansong Ji
Journal:  Biosci Rep       Date:  2019-04-23       Impact factor: 3.840

4.  Metabolomics-Based Pharmacodynamic Analysis of Zhuang Yao Shuang Lu Tong Nao Granules in a Rat Model of Ischemic Cerebral Infarction.

Authors:  Yang Zhai; Yangling Chen; Yihui Luo; Xiaoping Mei; Lin Wu; Xueni Mo; Min Zou; Mingzhao Zhou; Yangling Wu; Guangshan Zheng; Peng Yang; Qingyu He; Rui Chen
Journal:  Anal Cell Pathol (Amst)       Date:  2022-07-05       Impact factor: 4.133

5.  The Chinese medicine Sini-San inhibits HBx-induced migration and invasiveness of human hepatocellular carcinoma cells.

Authors:  Hung-Jen Lin; Shung-Te Kao; Yu-Miao Siao; Chia-Chou Yeh
Journal:  BMC Complement Altern Med       Date:  2015-10-07       Impact factor: 3.659

Review 6.  Preclinical Models for Investigation of Herbal Medicines in Liver Diseases: Update and Perspective.

Authors:  Hor-Yue Tan; Serban San-Marina; Ning Wang; Ming Hong; Sha Li; Lei Li; Fan Cheung; Xiao-Yan Wen; Yibin Feng
Journal:  Evid Based Complement Alternat Med       Date:  2016-01-28       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.